Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

Moderna Inc. on Thursday touted progress toward new vaccine approvals but said it will rein in its research and development ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...